Plavix, Clopidogrel News

From the HeartDrug Research Laboratories, Johns Hopkins University, Towson, Maryland ; and Department of Cardiology, Division of Medicine, Oslo University Hospital Ulleval and Institute for Clinical Sciences, University of Oslo, Oslo, Norway .

Modern medicine has become a myriad of published recommendations and guidelines for the standardization of treatment.

A price check of five blockbuster drugs that now have generics on the market, including Lipitor for cholesterol and the blood-thinner Plavix, shows significant price differences depending on which pharmacy you shop.

May 14, 2013. Patients with coronary artery disease who undergo treatment at the University of Maryland Medical Center now can receive long-term therapy based on information found in their genes.

The French Competition Authority said on Tuesday it fined drugmaker Sanofi 40.6 million euros over what it called a smear campaign aimed at stifling generic competition to its blood thinner, Plavix.

A study in this month's issue of the Alimentary Pharmacology & Therapeutics investigates colonoscopic post-polypectomy bleeding in patients on continued clopidogrel therapy.

If your insurance has ever stopped covering a prescription drug or you don't have coverage at all, you know how quickly costs can mount.

Within the past decade, the variability in pharmacodynamic response and moderate antiplatelet efficacy of clopidogrel has raised major concerns, in particular because it is associated with an increased risk for ischemic events in PCI patients.

From the Department of Neurology, Drum Tower Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China ; Department of Neurology , and Department of Clinical Laboratory , Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, PR China; and Nanjing Rentian Biotech Co, Ltd, Nanjing, Jiangsu, PR China .

The authors raise the possibility that even short-term TT is hazardous with regard to bleeding risk, without a safe therapeutic window.

Recent studies have advocated for continued clopidogrel as post-polypectomy bleeding rates have been similar to those in the general population not on antithrombotic therapy.

Bristol-Myers Squibb Co. missed analysts' sales and profit estimates in the first quarter as attention turned from its former best-sellers to the company's promising experimental drugs.

A study published ahead of print in the Alimentary Pharmacology & Therapeutics reports colonoscopic post-polypectomy bleeding in patients on continued clopidogrel therapy.

Bristol-Myers Squibb is scheduled to announce its results for Q1 2013 on April 25.